drugset
drugset / Trial / NCT07483437

A Study of HS-20136-2 in Healthy Participants

NCT07483437 ↗

Phase 1 Not yet recruiting 38 enrolled Jiangsu Hansoh Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindBasic science

Summary

This is a randomized, double-blind,placebo-controlled phase I clinical study.The main purpose is to assess the safety and tolerability of single subcutaneous administration of HS-20136-2 injection in healthy participants.

Timeline

Start
2026-05-15
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject HS-20136-2 Unknown — Subcutaneous

Indications

No indication recorded.